Antidepressant Use During Pregnancy: What the Venlafaxine Rat Study Reveals About Fetal Heart Development and Serotonin Signaling

Table of Contents

• Key Points
• Understanding the Issue: Antidepressants and Pregnancy
• Why This Study Was Needed
• Inside the Study: How the Research Was Conducted
• Key Findings: What the Researchers Discovered
• How Serotonin Signaling Works — And Why It Matters in Fetal Development
• Clinical Implications: What This Means for Patients
• Study Limitations: What This Research Cannot Tell Us
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In a rat study, venlafaxine increased fetal heart anomalies and altered serotonin signaling in the placenta and fetal heart.
• The study found sex-specific changes: SERT expression increased in female fetal hearts but not in males.
• Venlafaxine increased the placental index, suggesting disrupted fetal-placental growth relationships.
• This animal research does not prove identical risks in humans; human studies have been inconsistent.
• Pregnant patients taking venlafaxine should not stop abruptly and should discuss options with their doctor.

Understanding the Issue: Antidepressants and Pregnancy

Depression and anxiety are common during pregnancy, affecting roughly 10% to 20% of expecting mothers. When these conditions are severe, doctors often prescribe antidepressant medications to protect the mother's mental health — a factor that itself is critical for the well-being of both mother and baby.

Among the most frequently prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs). These drugs work by increasing the levels of certain brain chemicals — serotonin and norepinephrine — which help regulate mood.

Venlafaxine, sold under brand names such as Effexor, is one of the most commonly prescribed SNRIs. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and other conditions. But like many medications, its safety during pregnancy has been a source of ongoing scientific debate.

Some studies in humans have suggested a possible link between SNRI/SSRI use in early pregnancy and a slightly increased risk of congenital heart defects (heart problems present at birth). Other studies have found no such link. This inconsistency has left both doctors and patients uncertain about the safest course of action.

Why This Study Was Needed

The human studies published so far have produced conflicting results. Some suggest a connection between antidepressant use in early pregnancy and heart defects in newborns, while others do not. These discrepancies may stem from differences in study design, the specific medications examined, dosages used, or the difficulty of separating the effects of the drug from the effects of the underlying depression itself.

Given these uncertainties, researchers at McGill University and the Institut National de la Recherche Scientifique (INRS) in Canada decided to take a closer look at the biological mechanisms involved. Their goal was to determine whether venlafaxine, when administered during pregnancy, could directly cause heart defects in developing offspring — and if so, through what biological pathway.

The study was led by Laetitia Laurent, Chunwei Huang, Sheila R. Ernest, Anick Berard, Cathy Vaillancourt, and Barbara F. Hales. It was supported by multiple Canadian research organizations, including the Réseau Québécois de Recherche sur les Médicaments, the Research Chair on Medications and Pregnancy, the Fonds de Recherche du Québec (FRQ) Santé, McGill University, the March of Dimes Social and Behavioral Sciences Research program, and the Réseau Québécois de la Reproduction (RQR).

The researchers specifically tested the hypothesis that exposure to venlafaxine in the womb increases the incidence of fetal heart defects and disrupts serotonin signaling in both the placenta and the fetal heart.

Inside the Study: How the Research Was Conducted

The study used timed-pregnant Sprague Dawley rats, a standard animal model for developmental toxicity research. This strain of rat is widely used in teratology studies (research on birth defects) because its reproductive and developmental biology is well understood and reasonably similar to that of humans in many respects.

Pregnant rats were divided into five groups and given daily oral doses of venlafaxine hydrochloride (the active ingredient in Effexor) by gavage — a method in which the drug is delivered directly into the stomach using a feeding tube, similar to taking a tablet or capsule orally.

The doses used were:

• 0 mg/kg/day (control group — no drug given)
• 3 mg/kg/day (low dose)
• 10 mg/kg/day (low-to-moderate dose)
• 30 mg/kg/day (moderate-to-high dose)
• 100 mg/kg/day (high dose)

1. Treatment began on gestation day 8 and continued daily through gestation day 20. (In rats, gestation lasts about 21–23 days, so this covers the majority of pregnancy, including the period of organ development.)
2. On gestation day 21, the fetuses were surgically delivered and carefully examined.
3. Researchers recorded the number of live fetuses, fetal body weights, and placental weights.
4. Each fetus was examined for external malformations (visible abnormalities on the outside of the body) and internal malformations (including a detailed inspection of the heart).
5. Samples of placenta and fetal heart tissue were collected for analysis of gene expression — that is, which genes were turned on or off and at what levels.
6. Both messenger RNA (mRNA) levels (the blueprint copied from DNA to make proteins) and protein levels were measured for key serotonin-related components.

The researchers specifically focused on several key molecules involved in serotonin signaling: the serotonin transporter (SERT, encoded by the gene Slc6a4), the serotonin 2B receptor (5-HT_2B, encoded by the gene Htr2b), and fibroblast growth factor 8 (FGF8), a signaling molecule important in heart development.

Key Findings: What the Researchers Discovered

1. General pregnancy outcomes: No overall toxicity at lower doses

In the absence of maternal toxicity, venlafaxine had no effect on the number of live fetuses, fetal body weights, or external morphology — meaning the fetuses' outward appearance was normal. This is reassuring in the sense that the drug did not cause widespread harm to the pregnancy or grossly visible birth defects.

2. Placental index increased significantly

However, the researchers found that venlafaxine significantly increased the placental index. The placental index is the ratio of fetal body weight to placental weight (in this study described as fetal body/placental weight ratio). An altered placental index suggests that the relationship between fetal growth and placental size has been disrupted — which can be a sign that the placenta is not functioning optimally. This is an important finding because the placenta is the organ that supplies oxygen and nutrients to the developing baby and removes waste products.

3. Fetal cardiac anomalies increased

The most striking finding was that venlafaxine exposure significantly increased the incidence of fetal cardiac anomalies — structural abnormalities in the developing heart. In the abstract, the researchers specifically note that this occurred even though the fetuses had no external malformations, meaning the heart defects were internal and would not have been visible without a detailed examination.

Congenital heart defects are the most common type of birth defect in humans, affecting approximately 1 in every 100 babies. Common examples include ventricular septal defects (holes in the wall between the heart's lower chambers), atrial septal defects (holes in the upper chambers), and abnormalities of the great vessels. The study's authors specifically listed ventricular septal defect among the keywords of the paper, indicating this may be among the anomalies observed.

4. Serotonin transporter (SERT) expression decreased in the placenta

Venlafaxine exposure caused a decrease in the expression of the serotonin transporter (SERT/Slc6a4) in the placenta, at both the transcript (mRNA) and protein levels. The serotonin transporter is responsible for recycling serotonin — removing it from the space between cells so it can be reused. Its job is to regulate how much serotonin is available in a given tissue.

When SERT levels drop in the placenta, serotonin dynamics are disrupted. This matters because serotonin is not just a brain chemical — it also acts as a growth factor that helps regulate fetal development, including heart development. The placenta itself produces serotonin and supplies it to the fetus during early pregnancy, before the fetus's own serotonin production systems are fully developed.

5. SERT expression increased in female fetal hearts only

In a striking sex-specific difference, venlafaxine increased SERT expression in the hearts of female fetuses, but not male fetuses. This finding raises questions about whether male and female fetuses respond differently to antidepressant exposure — a topic that has received increasing attention in recent years.

Sex differences in drug response during development are not unusual, but they highlight the complexity of how medications affect developing organisms and suggest that the risk of heart anomalies may differ between male and female fetuses.

6. Serotonin 2B receptor and FGF8 expression increased in fetal hearts

The researchers also found that venlafaxine induced the expression of the serotonin 2B receptor (5-HT_2B/Htr2b) and of fibroblast growth factor 8 (FGF8) in the fetal heart.

These are important molecules in heart development:

• The 5-HT_2B receptor is one of the receptors that serotonin binds to. It plays a crucial role in heart development, including the formation of the heart valves and the proper development of the ventricles (the heart's main pumping chambers).
• FGF8 is a signaling protein that directs cells during embryonic development. It is critical for the formation of the heart, particularly the outflow tract — the pathway that carries blood from the heart to the rest of the body. Abnormalities in FGF8 signaling have been linked to congenital heart defects.

The fact that both of these molecules increased in response to venlafaxine suggests a plausible mechanism: the drug disrupts normal serotonin signaling, which then alters the expression of downstream molecules like FGF8, ultimately leading to structural abnormalities in the heart.

Statistical significance was reported for the key outcomes — the placental index changes and the increased cardiac anomaly rate — meaning the results were unlikely to be due to random chance. Animal teratology studies like this one typically look for dose-response relationships, where higher doses produce greater effects, although the abstract groups the findings across the dose range tested.

How Serotonin Signaling Works — And Why It Matters in Fetal Development

Most people think of serotonin as a brain chemical that affects mood. In reality, serotonin acts on nearly every organ system in the body, and its role during embryonic development is particularly fascinating.

Serotonin is synthesized (created) in the placenta and in specific regions of the developing fetus. It acts as a growth factor — not just a neurotransmitter — participating in the regulation of cell division, cell migration, and programmed cell death. All of these processes are essential for building a properly structured heart.

Here's how the system normally works:

1. Serotonin is released from cells and binds to receptors on target cells. The 5-HT_2B receptor is one of these receptors.
2. The serotonin transporter (SERT) then "recycles" serotonin by pumping it back into the cells that released it, turning off the signal and maintaining proper levels.
3. In the developing heart, serotonin signaling influences the migration of cardiac neural crest cells — cells that help form the heart's outflow tract and septa (the walls dividing the heart's chambers).
4. These signals interact with other developmental pathways, including fibroblast growth factor signaling (FGF8), to produce a normally structured heart.

When antidepressant drugs like venlafaxine block the serotonin transporter, they disrupt this carefully balanced system. In the mother's brain, this blockade may relieve depression symptoms. But in the placenta and fetal heart, the altered serotonin levels may change gene expression in ways that interfere with heart development.

It is important to note that venlafaxine blocks the serotonin transporter specifically — it prevents serotonin from being recycled — which is why it is called a "serotonin reuptake inhibitor." The study shows that in the placenta, the body may attempt to compensate by reducing SERT production further (the observed decrease in SERT expression), while in female fetal hearts, the opposite response occurred (increased SERT expression). These tissue-specific and sex-specific responses highlight the complexity of drug effects during development.

Clinical Implications: What This Means for Patients

This study is an important piece of the puzzle, but it must be interpreted carefully.

First, the good news from the study: venlafaxine did not increase the number of fetal deaths or cause visible external birth defects in rats, at least not at doses below those causing maternal toxicity. This suggests that the drug is not a broad-spectrum teratogen (an agent that causes many different kinds of birth defects).

However, the increased rate of cardiac anomalies is concerning. Congenital heart defects range from mild conditions that resolve on their own to severe lifelong complications requiring multiple surgeries. If venlafaxine does increase the risk of heart defects in human babies, even by a small amount, this could translate to thousands of additional cases worldwide each year, given how widely the drug is prescribed.

The study also introduces the idea that the placenta itself may respond to antidepressant exposure in ways that affect fetal development. This is a relatively new area of research — the placenta was long considered a passive filter, but researchers now recognize it as a dynamic endocrine organ that actively regulates the fetal environment.

For patients, the takeaway messages are:

• Antidepressant use during pregnancy is a complex decision that requires balancing the mother's mental health against potential risks to the baby.
• Untreated depression and anxiety during pregnancy also carry risks — including low birth weight, preterm birth, poor maternal self-care, and postpartum depression.
• Animal studies like this one cannot directly predict what will happen in humans, but they do provide biological plausibility for associations seen in some human epidemiological studies.
• Not all antidepressants carry the same risks. SSRIs such as sertraline (Zoloft) have been more extensively studied during pregnancy; some are considered lower-risk options. Venlafaxine is generally considered a second-line treatment for pregnancy because of less extensive safety data.

Study Limitations: What This Research Cannot Tell Us

It is essential to emphasize that this is an animal study. The findings in rats do not automatically translate to humans. There are several important limitations to consider.

1. Species differences. Rats and humans have different rates of drug metabolism, different placental structures, and different developmental timelines. The rat placenta is structurally different from the human placenta (the rat has a different type of placentation), so the effects on placental serotonin signaling may not fully mirror what happens in human pregnancies.

2. High doses. The doses used in this study ranged from 3 to 100 mg/kg/day in rats. When adjusted for body surface area differences between rats and humans, even the "low" human-equivalent doses are often higher than typical therapeutic doses in humans. However, it is worth noting that even the lowest dose (3 mg/kg/day) is roughly equivalent to a moderate human dose, and the standard human dose of venlafaxine is between 75 and 225 mg/day.

3. Timing differences. The drug was given from gestation day 8 to day 20 in rats, covering a larger fraction of pregnancy than a typical first-trimester exposure in humans. The highest vulnerability period for causing structural heart defects in humans is the first trimester — between weeks 3 and 8 of pregnancy — when the heart is forming. Rat heart development occurs over a compressed timeline, making direct comparison difficult.

4. No p-values or effect size details in this summary. The published abstract states that findings were "significant" without listing exact p-values or the percentage increase in cardiac anomaly rates. The full article (available to subscribers) contains these details.

5. Mechanism proposed but not definitively proven. The researchers propose that the cardiac anomalies are mediated through altered serotonin signaling, but demonstrating a correlation (changes in SERT and receptor expression coinciding with heart defects) is not the same as proving causation. Follow-up studies would need to block the signaling changes and see whether the heart defects disappear.

6. Relevance to humans remains uncertain given inconsistent human studies. Some epidemiological studies in humans report no increased risk of congenital heart defects with venlafaxine, while others report a modest increase. The scientific community is still divided on this question.

Recommendations for Patients

If you are pregnant, planning to become pregnant, or currently taking venlafaxine, this study does not mean you should stop your medication abruptly. That decision should be made with your healthcare provider. Here are some steps to consider:

1. Do not stop your antidepressant cold turkey. Abruptly discontinuing venlafaxine can cause withdrawal symptoms such as dizziness, nausea, headache, and "brain zaps," and can lead to worsening of depression or anxiety. These effects themselves could be harmful to both you and your pregnancy.
2. Talk to your doctor (psychiatrist, obstetrician, or both) about your options. Bring this research abstract to the conversation if you like. Ask about the relative risks and benefits of continuing your current medication, switching to a different medication with more pregnancy safety data, or tapering off medication with psychosocial support instead.
3. Understand the risk magnitude. Even if venlafaxine does increase the risk of heart defects, the absolute increase in risk appears to be small, and the baseline risk of congenital heart defects is about 1 in every 100 live births. A modest relative increase would not change the absolute risk dramatically for an individual pregnancy.
4. Ask about prenatal screening. If you take venlafaxine during pregnancy, you may be offered additional prenatal testing, such as a detailed fetal echocardiogram (an ultrasound of the fetal heart) at 18 to 22 weeks of pregnancy, to check for heart structure abnormalities.
5. Consider other treatment options. Psychotherapy (cognitive behavioral therapy, interpersonal therapy) is effective for mild to moderate depression and has no known risks to the fetus. For severe depression, medication is often necessary, but combining medication with therapy may allow for a lower dose.
6. Remember that the mother's mental health matters for the baby too. Untreated severe depression is associated with preterm birth, low birth weight, and adverse neurodevelopmental outcomes. In some cases, staying on medication is the safest choice for both mother and baby.

Frequently Asked Questions

What did the study find about venlafaxine and fetal heart anomalies?

In pregnant rats given venlafaxine, the rate of fetal heart anomalies increased, even though no external birth defects appeared. The drug also raised the placental index and altered serotonin signaling in the placenta and fetal heart. These findings suggest a possible biological pathway, but this was an animal study, not proof of identical risks in humans.

Is this study proof that venlafaxine causes heart defects in human babies?

No. This was a rat study, and animal results do not automatically apply to humans. Human studies so far have been inconsistent, with some suggesting a slight increase in heart defect risk and others finding none. The study offers clues about possible biological mechanisms but does not prove that venlafaxine causes heart defects in human babies.

Should I stop taking venlafaxine if I am pregnant?

Do not stop abruptly. Suddenly stopping venlafaxine can cause withdrawal symptoms and worsening depression, which may harm both you and your pregnancy. Talk to your doctor about the risks and benefits of continuing, switching, or tapering off. Untreated severe depression also carries risks to the baby, so shared decision-making with a healthcare provider is essential.

What are the limitations of this animal study?

Key limitations include species differences in metabolism and placental structure, higher drug doses than typical human doses, and differences in timing of exposure. The mechanism was proposed but not proven, and human studies remain inconsistent. Also, the abstract reported significance without exact p-values or effect sizes. Therefore, direct translation to human pregnancy is uncertain.

What should I discuss with my doctor if I take venlafaxine and am pregnant?

Ask about the relative risks and benefits of continuing your medication, switching to a different antidepressant with more pregnancy safety data, or tapering off with psychosocial support. Discuss whether additional prenatal screening, like a detailed fetal echocardiogram, might be offered. Remember that untreated severe depression also carries risks to both mother and baby.

When should a pregnant patient taking venlafaxine seek a second opinion about her treatment options?

Seek a second opinion when you are pregnant or planning pregnancy and taking venlafaxine, especially when deciding whether to continue, switch, or taper the medication. Venlafaxine is generally considered a second-line treatment during pregnancy because less safety data is available; some SSRIs are viewed as lower-risk options. Stopping abruptly can cause withdrawal and worsen depression, which itself carries risks such as low birth weight and preterm birth. Animal research shows increased fetal heart anomalies and altered serotonin signaling, though direct human risk remains uncertain. A second opinion can help clarify the balance between maternal mental health and potential fetal risks, including prenatal cardiac screening. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: In utero exposure to venlafaxine, a serotonin–norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat - Laurent - 2016 - Birth Defects Research Part A Clinical and Molecular Terat

Authors: Laetitia Laurent, Chunwei Huang, Sheila R. Ernest, Anick Berard, Cathy Vaillancourt, and Barbara F. Hales

Journal: Birth Defects Research Part A: Clinical and Molecular Teratology

Publication details: Volume 106, Issue 12, December 2016, Pages 1044–1055. First published online: July 7, 2016. Issue published online: December 21, 2016.

DOI: https://doi.org/10.1002/bdra.23537

Funding: Supported by the Réseau Québécois de Recherche sur les Médicaments (B.F.H. and A.B.), the Research Chair on Medications and Pregnancy (A.B.), the Fonds de Recherche du Québec (FRQ) Santé, McGill University (B.F.H.), the March of Dimes Social and Behavioral Sciences Research (#12-FY12-179, C.V.), and the Réseau Québécois de la Reproduction (RQR)-FRQ-Nature et Technologie (B.H. and C.V.).

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace medical advice from a qualified healthcare professional. If you are pregnant or planning a pregnancy and take medication, always consult your doctor before making any changes.